Диссертация (1141398), страница 16
Текст из файла (страница 16)
Mastrangelo // Journal of clinical oncology. – 1995. – V.13. – P.796-797.102.Betageri, G.V. Water soluble polymers for pharmaceutical applications /V.G. Kadajji, G.V. Betageri // Polymers. – 2011. – V.3(4). – P. 1972-2009.103.Bibby, M.C. Anti-tumour activity of TCNU in a panel of transplantablemurine colon tumours / C.M. Bibby, J.A. Double, C.M. Morris // European journalof cancer and clinical oncology. – 1988.
– V.24. – P. 1361-1364.104.Bohanec, S. Using different experimental designs in drug-excipientcompatibility studies during the preformulation development of a stable solid dosageformulation / S. Bohanec [et al.] // Acta Chimica Slovenica. – 2010. – V. 57. – P.895-903.105.Buckner, J.C. A phase III study of radiation therapy plus carmustine withor without recombinant interferon-alpha in the treatment of patients with newlydiagnosed high-grade glioma / J.C. Buckner [et al.] // Cancer. – 2001. – V. 92, №2.
–P. 420-433.106.CancerFactsheet(электронныйресурс).URL:http://www.who.int/mediacentre/factsheets/fs297/en/ (дата обращения 05.02.2017).107.Chadha, R. Drug–excipient compatibility screening - role of thermoanalytical and spectroscopic techniques / R. Chadha, S. Bhandari // Journal ofpharmaceutical and biomedical analysis. – 2014. – V. 87. – P. 82-97.110108.Chaudhari, S.P. Pharmaceutical excipients: a review / S.P. Chaudhari, P.S.Patil // International journal of advances in pharmacy, biology and chemistry.
–2012. – V.1, №1. – P. 21-34.109.Chollet, P. Results of two phase II trials with cystemustine in advancedmalignant melanoma / P. Chollet [et al.] // Annals of oncology. – 1994. – V. 5. – P.144a.110.Dal Pan, G. Preliminary analysis of the Giladel treatment protocol / G. DalPan, L. Butler, M. Schactman // Abstract presented at the ASCO annual meeting. –1997. – P. 338A.111.Dhakane, V.D. A validated stability-indicating HPLC related substancesmethod for carmustine in bulk drug / V.D.
Dhakane, M.B. Ubale // Elixir AppliedChemistry. – 2012. – V. 50. – P. 10383-10386.112.Favier, M. Stability of carmustine in polyvinyl chloride bags andpolyethylene-lined trilayer plastic containers / M. Favier [et al.] //American journalof health-system pharmacy. – 2001. – V. 58. – P. 238-241.113.Fisusi, F.A. Lomustine nanoparticles enable both bone marrow sparing andhigh brain drug levels – a strategy for brain cancer treatmens / F.A. Fisusi [et al.] //Pharmaceutical research. – 2016. – V. 33.
– P. 1289-1303.114.Frederiksson K., Lundgren P., Landersjoe L. Stability of carmustinekinetics and compatibility during administration / K. Frederiksson, P. Lundgren, L.Landersjoe // Acta pharmaceutica suecica. – 1986 –V.23. – P. 115-124.115.Friedman, H.S. Can alkylguanine-DNA alkyltransferase depletion enhancealkylator activity in the clinic? / H.S. Friedman // Clinical cancer research. – 2000. –V. 6. – P. 2967-2968.116.ресурс).Gliadel Wafer (polifeprosan 20 with carmustine implant) (электронныйURL:http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/237/gliadel-wafer-polifeprosan-20-with-carmustine-implantобращения 01.02.2016).(дата111117.Gorbunova, V.A.
Therapeutic results in small cell lung cancer withextensive disease / V.A. Gorbunova [et al.] // International congress for LungCancer. – Athens, 1994. – P. 177.118.Hadji-Minaglou-Gonzalvez,M.F.Effectsoftemperature,solutioncomposition, and type of container on the stability and absorption of carmustine /M.F. Hadji-Minaglou-Gonzalvez, A. Gayte-Sorbier, C.B. Airauto, M.
Verdier //Clinical therapeutics. – 1992. – V.14. – P. 821-824.119.Hardwicka, L.M. A proposed rationale and test methodology forestablishment of acceptance criteria for vacuum integrity testing of pharmaceuticalfreeze dryers / L.M. Hardwicka [et al.] // European journal of pharmaceutics andbiopharmaceutics. – 2013. – V. 85, №2. – P.236–239.120.URL:Harris, T. How freeze-drying works / T. Harris // (электронный ресурс).http://science.howstuffworks.com/innovation/edible-innovations/freeze-drying2.htm (дата обращения 01.05.2016).121.Hartley-Asp, B. Anti-tumor, toxicological and pharmacokinetic propertiesof a novel taurine-based nitrosourea (TCNU) // B. Hartley-Asp [et al.] //Investigation new drugs.
– 1998. – V. 6. – P. 19-30.122.Heitz, E. Filtermedien und Umkehrsmase – «Sauberes» Wasser // Pharm.Ind. – 1988. – №2. – P. 53-54.123.Iliadis, A. Pharmacokinetics and pharmacodynamics of nitrosoureafotemustine: a French Cancer Centre Multicentric study / A. Iliadis [et al.] //European journal of cancer. – 1996. – V.
32A. – P. 445-460.124.Jacguillat, C. Final report of the phase II study of the nitrosoureafotemustine in 153 patients with dissiminated malignant melanoma including brainmetastases / C. Jacguillat [et al.] // Proc. AACR. – 1989. – V. 30. – P. 1088.125.Kitajima, K. Chemotherapy of chronic myelogenous leukemia--VP(M)regimen initiated during its chronic phase, and evaluation of MCNU in the phase ofblastic crisis / K. Kitajima [et al.]// Gan To Kagaku Ryoho. – 1989. – V. 16, №11. –P. 3573-3579.112126.Kornblith, P.L. Response of cultured human brain tumors to nitrosoureas:correlation with clinical data / P.L.
Kornblith, B.H. Smith, L.A. Leonard // Cancer. –1981. – V.47, №2. – P. 255-265.127.Kraan, H. Development of thermostable lyophilized inactivated poliovaccine / H. Kraan, P. van Herpen, G. Kersten, J.-P. Amorij // Pharmaceuticalresearch. – 2014. – V. 31. – P. 2618-2629.128.Laquerriere, A. Nitrosoureas lomustine, carmustine and fotemustineinduced hepatotoxic perturbations in rats: biochemical, morphological and flowcytometry studies / A. Laquerriere [et al.] // European journal of cancer and clinicaloncology.
– 1991. – V. 27, №5. – P. 630-638.129.Laskar, P.A. Degradation of carmustine in aqueosus media / P.A. Laskar,J.W. Ayres // Journal of pharmaceutical science. – 1977. – V. 66, №8. – P. 10731076.130.Laskar, P.A. Degradation of carmustine in mixed solvent and nonaqueousmedia / P.A. Laskar, J.W. Ayres // Journal of pharmaceutical science. – 1977. – V.66, №8. – P. 1076-1078.131.Levit, G.L. Nω-alkylnitrosocarbomoyl-α,ω-diaminocarboxylic acids.
3.Synthesis and antitumor activity of Nε-nitroso-Nε-[N’-2chloroethyl)carbomoyl]-Llysine and Nε-[N’-2chloroethyl)-N-nitroso-carbomoyl]-L-lysine // G.L. Levit [et al.]// Pharmaceutical chemistry journal. – 1996. – V. 30, №5. – P. 306-309.132.Loftsson, T. Degradation of lomustine (CCNU) in aqueous solutions / T.Loftsson, H. Fridriksdottir // International journal of pharmaceutics. – 1990.
– V. 62,№2-3. – P. 243-247.133.Loftsson, T. Degradation of tauromustine (TCNU) in aqueous solutions / T.Loftsson, J. Baldvinsdottir // Acta Pharmaceutica Nordica. – 1992. – V. 4, №3. – P.129-132.134.Ludlum, D.B. Mechanism of action of the nitrosoureas—II. Formation offluoroethylguanosine from the reaction of bis-fluoroethyl nitrosourea and guanosine/ D.B. Ludlum, W.P. Tong // Biochemical pharmacology. – 1978. – V.
27, №20. – P.2391-2394.113135.Makary, P. Principles of salt formation / P. Makary // UK journal ofpharmaceutical and biosciences. – 2014. – V. 2, №4. – P. 1-4.136.Meulemans, A. Comparative diffusion study of two nitrosoureas:carmustine and fotemustine in normal rat brain, human and rat brain biopsies / A.Meulemans [et al.] // Chemotherapy. – 1991. – V. 37. – P. 86-92.137.Mohanachandran, P.S.
Enhancement of solubility and dissolution rate anoverviem / P.S. Mohanachandran, P.G. Sindhumol, T.S. Kiran // Pharmacie globale:international journal of comprehensive pharmacy. – 2010. – V.1. – Is. 4. – P. 1-10.138.Molineux, G. Hematopoietic effects of TCNU in mice / G. Molineux, R.Schofield, N.G. Testa // Cancer treatment reports. – 1987.
– V.71, №9. – P. 837-841.139.Nagai, M. Therapeutic effect of ranimustine (MCNU) on essentialthrombocythemia and polycythemia vera / M. Nagai [et al.] // Gan To KagakuRyoho. – 1989. – V. 15, №12. – P. 3267-3270.140.Nishath, F. Drug-excipient interaction and its importance in dosage formdevelopment / F. Nishath [et al.] // Journal of applied pharmaceutical science. –2011. – V. 1, № 06. – P.
66-71.141.Patel, H. New pharmaceutical excipients in solid dosage forms – A review /H. Patel, V. Shah, U. Upadhyay // International journal of pharmacy & life sciences.– 2011. – V. 2, №8. – 1006-1019.142.Patel, P. Drug-excipient compatibility studies: first step for dosage formdevelopment / P. Patel [et al.] // The pharma innovation journal. – 2015. – V. 4, №5.– P. 14-20.143.Parr, A. The effect of excipients on the permeability of BCS class IIIcompounds and implications for biowaivers // A.
Parr [et al.] // Pharmaceuticalresearch. – 2016. – V. 33. – P. 167-176.144.Perevodchikova, N.I. Aranoza – a new nitrosourea derivative withantitumor action. Phase I-II trials / N.I. Perevodchikova [et al.] // Internationaljournal clinical chemotherapy. – 1992. – V. 5, №4. – P. 231-236.145.Petit, T. Complete remission seven years after treatment for metastaticmalignant melanoma / T. Petit [et al.] // Cancer. – 1996. – V. 77. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
